We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+21.43%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$277M
AUM Growth
-$90.1M
Cap. Flow
-$75.2M
Cap. Flow %
-27.11%
Top 10 Hldgs %
45.56%
Holding
64
New
13
Increased
10
Reduced
20
Closed
18

Top Buys

Rank Stock Value
1
VTGN icon
VistaGen Therapeutics
VTGN
+$10.7M
2
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$7.95M
3
EPIX
ESSA Pharma
EPIX
+$6.67M
4
CMRX
Chimerix, Inc.
CMRX
+$6.5M
5
ACRS icon
Aclaris Therapeutics
ACRS
+$6.21M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$18.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$14M
3
IMVT icon
Immunovant
IMVT
+$13.1M
4
SAGE
Sage Therapeutics
SAGE
+$11.3M
5
CMPS
Compass Pathways
CMPS
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 91.38%
2 Financials 5.21%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
26
DELISTED
Apellis Pharmaceuticals
APLS
$4.86M 1.75%
113,161
-53,893
-32% -$2.55M
GYRE icon
27
Gyre Therapeutics
GYRE
$714M
$4.74M 1.71%
125,267
-55,733
-31% -$2.55M
RAPT
28
DELISTED
RAPT Therapeutics
RAPT
$4.45M 1.6%
25,036
-1,164
-4% -$192K
OBIO icon
29
Orchestra BioMed
OBIO
$249M
$4.39M 1.58%
392,500
– –
CLSD
30
DELISTED
Clearside Biomedical
CLSD
$3.99M 1.44%
107,600
+24,267
+29% +$1.22M
EYPT icon
31
EyePoint Inc
EYPT
$1.08B
$3.87M 1.4%
+381,145
New +$4.29M
RNAC icon
32
Cartesian Therapeutics
RNAC
$257M
$3.72M 1.34%
+27,433
New +$3.41M
CMPS
33
Compass Pathways
CMPS
$1.83B
$3.31M 1.19%
90,000
-229,000
-72% -$10M
IOVA icon
34
Iovance Biotherapeutics
IOVA
$2.77B
$3.09M 1.11%
97,574
-67,226
-41% -$2.79M
VINCW
35
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
$2.1M 0.76%
+520,000
New +$2.11M
RNAM
36
DELISTED
Avidity Biosciences
RNAM
$1.79M 0.64%
82,000
-164,200
-67% -$4.02M
STOK icon
37
Stoke Therapeutics
STOK
$2.06B
$1.75M 0.63%
45,000
-47,500
-51% -$2.7M
MRTX
38
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.54M 0.56%
+9,000
New +$1.78M
INSM icon
39
Insmed
INSM
$28.7B
$1.45M 0.52%
+42,500
New +$1.62M
CBAY
40
DELISTED
Cymabay Therapeutics
CBAY
$1.43M 0.52%
315,341
-14,659
-4% -$78.9K
RETA
41
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$1.4M 0.5%
+14,000
New +$1.63M
FDMT icon
42
4D Molecular Therapeutics
FDMT
$552M
$868K 0.31%
20,000
– –
NVAX icon
43
Novavax
NVAX
$1.27B
$569K 0.21%
3,136
+636
+25% +$127K
PMVP icon
44
PMV Pharmaceuticals
PMVP
$62.9M
$456K 0.16%
13,856
-1,144
-8% -$45.1K
CPRX
45
DELISTED
Catalyst Pharmaceutical
CPRX
$360K 0.13%
+78,000
New +$310K
NUVB.WS
46
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$249K 0.09%
+93,332
New +$270K
ALDX icon
47
Aldeyra Therapeutics
ALDX
$95.9M
– –
-192,500
Closed -$1.32M
ANNX icon
48
Annexon
ANNX
$918M
– –
-25,000
Closed -$626K
AXSM icon
49
Axsome Therapeutics
AXSM
$10.8B
– –
-6,000
Closed -$489K
CCCC icon
50
C4 Therapeutics
CCCC
$402M
– –
-110,000
Closed -$3.64M
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return

Acuta Capital Partners's Q1 2021 Portfolio in Review

As of Q1 2021, Acuta Capital Partners held 64 positions worth $277M, down 25% from $367M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Acuta Capital Partners withdrew a net $75.2M in Q1 2021, closing 18 positions and reducing 20 holdings. Its most notable exit was Larimar Therapeutics, an estimated $18.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier, followed by Financials and Industrials.

Against the trend, Acuta Capital Partners opened a new position in Vincerx Pharma, Inc. Common Stock worth $7.6M.

  • Acuta Capital Partners's largest Q1 2021 buy was Vincerx Pharma, Inc. Common Stock: 19,700 shares worth $7.6M.
  • Acuta Capital Partners added most to VistaGen Therapeutics in Q1 2021, an estimated $10.7M increase.
  • Acuta Capital Partners's biggest Q1 2021 reduction was Celldex Therapeutics, cutting an estimated $14M.
  • Acuta Capital Partners fully exited Larimar Therapeutics in Q1 2021, selling an estimated $18.5M.
  • Acuta Capital Partners's ten largest holdings make up 46% of its $277M portfolio in Q1 2021.
  • Acuta Capital Partners opened 13 new positions and closed 18 in Q1 2021.
  • Acuta Capital Partners's portfolio value fell 25% quarter-over-quarter to $277M.

Based on Acuta Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.